Cellectis Presents Preclinical Data on.HEAL-101 at ESGCT 2026
Cellectis announced presentation of preclinical data on.HEAL-101, highlighting APOC3 editing and marked triglyceride reduction.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cellectis Presents Preclinical APOC3 Editing Data for.HEAL-101
Cellectis presented preclinical data highlighting APOC3 editing and triglyceride reduction with.HEAL-101 at ESGCT 2026.
Cellectis Presents Preclinical APOC3 Editing Data at ESGCT 2026
The company reported 70% in vivo editing of human APOC3 and a 76% triglyceride reduction after a single administration. The headline identifies the therapy as.HEAL-101.
Cellectis Presents Preclinical APOC3 Editing Data at ESGCT 2026
Cellectis presented preclinical data highlighting APOC3 editing and triglyceride reduction with.HEAL-101 at ESGCT 2026.
Cellectis Presents Preclinical APOC3 Gene-Editing Data at ESGCT 2026
Cellectis presented preclinical data showing effective APOC3 gene editing and a marked reduction in triglycerides with.HEAL-101.
Cellectis presents preclinical APOC3 editing data at ESGCT 2026
The company says its preclinical data show effective APOC3 gene editing and a marked reduction in triglycerides with.HEAL-101.